01 enero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. Angioplasty of Femoral-Popliteal Arteries With Drug-Coated Balloons. 5-Year Follow-Up of the THUNDER Trial

Gunnar Tepe, MD∗; Beatrix Schnorr, DVM†; Thomas Albrecht, MD‡; Klaus Brechtel, MD§; Claus D. Claussen, MD§; Bruno Scheller, MD‖; Ulrich Speck, PhD†; Thomas Zeller, MD¶

Objectives: The purpose of this study was to evaluate the 5-year follow-up (FU) data of the THUNDER (Local Taxan With Short Time Contact for Reduction of Restenosis in Distal Arteries).

01 enero 2015

JACC: CARDIOVASCULAR INTERVENTIONS. The Impact of Extreme-Risk Cases on Hospitals’ Risk-Adjusted Percutaneous Coronary Intervention Mortality Ratings

Matthew W. Sherwood, MD, MHS∗; J. Matthew Brennan, MD, MPH∗; Kalon K. Ho, MD†; Frederick A. Masoudi, MD, MSPH‡; John C. Messenger, MD‡; W. Douglas Weaver, MD§; David Dai, MS∗; Eric D. Peterson, MD, MPH†

Objectives: The goal of this study was to examine the calibration of a validated risk-adjustment model in very high-risk percutaneous coronary intervention (PCI) cases and assess whether sites´ case mix affects their performance ratings.

13 enero 2016

CIRCULATION. Coronary Heart Disease. Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention. Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial

Michelle L. O’Donoghue, MD, MPH; Deepak L. Bhatt, MD, MPH; Gregg W. Stone, MD; Ph. Gabriel Steg, MD; C. Michael Gibson, MS, MD; Christian W. Hamm, MD; Matthew J. Price, MD; Jayne Prats, PhD; Tiepu Liu, PhD; Efthymios N. Deliargyris, MD; Kenneth W. Mahaffey, MD; Harvey D. White, DSc; Robert A. Harrington, MD; ; on Behalf of the CHAMPION PHOENIX Investigators*

Background: Cangrelor is an intravenous ADP receptor antagonist that leads to potent and reversible inhibition of platelet aggregation. The relative safety and efficacy of some antiplatelet drugs in women has been disputed.

10 noviembre 2015

CIRCULATION. Health Services and Outcomes Research. Effects of Ranolazine on Angina and Quality of Life After Percutaneous Coronary Intervention With Incomplete Revascularization. Results From the Ranolazine for Incomplete Vessel Revascularization (RIVER-PCI) Trial

Karen P. Alexander, MD; Giora Weisz, MD; Kristi Prather, MPH; Stefan James, MD; Daniel B. Mark, MD; Kevin J. Anstrom, PhD; Linda Davidson-Ray, MA; Adam Witkowski, MD, PhD; Angel J. Mulkay, MD; Anna Osmukhina, PhD; Ramin Farzaneh-Far, MD; Ori Ben-Yehuda, MD; Gregg W. Stone, MD; E. Magnus Ohman, MD

Background: Angina often persists or returns in populations following percutaneous coronary intervention (PCI). We hypothesized that ranolazine would be effective in reducing angina and improving quality of life (QOL) in incomplete revascularization (ICR) post-PCI patients.

13 enero 2016

CIRCULATION. Interventional Cardiology. Mechanisms of Very Late Drug-Eluting Stent Thrombosis Assessed by Optical Coherence Tomography

Masanori Taniwaki, MD; Maria D. Radu, MD, PhD; Serge Zaugg, MSc; Nicolas Amabile, MD, PhD; Hector M. Garcia-Garcia, MD, PhD; Kyohei Yamaji, MD, PhD; Erik Jørgensen, MD, DMSc; Henning Kelbæk, MD, DMSc; Thomas Pilgrim, MD; Christophe Caussin, MD; Thomas Zanchin, MD; Aurelie Veugeois, MD; Ulrik Abildgaard, MD, DMSc; Peter Jüni, MD; Stephane Cook, MD; Konstantinos C. Koskinas, MD, MSC; Stephan Windecker, MD; Lorenz Räber, MD, PhD

Background: The pathomechanisms underlying very late stent thrombosis (VLST) after implantation of drug-eluting stents (DES) are incompletely understood. Using optical coherence tomography, we investigated potential causes of this adverse event.

28 octubre 2015

CIRCULATION. Vascular Medicine. Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL)

Ioana R. Preston, MD; Kari E. Roberts, MD; Dave P. Miller, MS; Ginny P. Sen, MPH; Mona Selej, MD, MS; Wade W. Benton, PharmD; Nicholas S. Hill, MD; Harrison W. Farber, MD

Background: Long-term anticoagulation is recommended in idiopathic pulmonary arterial hypertension (IPAH). In contrast, limited data support anticoagulation in pulmonary arterial hypertension (PAH) associated with systemic sclerosis (SSc-PAH). We assessed the effect of warfarin anticoagulation on survival in IPAH and SSc-PAH patients enrolled in Registry to Evaluate Early and Long-term PAH Disease Management (REVEAL), a longitudinal registry of group I PAH.

17 agosto 2015

CIRCULATION. Arrhythmia/Electrophysiology. Cryoballoon Versus Open Irrigated Radiofrequency Ablation in Patients With Paroxysmal Atrial Fibrillation. The Prospective, Randomized, Controlled, Noninferiority FreezeAF Study

Armin Luik, MD; Andrea Radzewitz, PsyD; Meinhard Kieser, ScD; Marlene Walter; Peter Bramlage, MD; Patrick Hörmann, MD; Kerstin Schmidt, MD; Nicolas Horn, MD; Maria Brinkmeier-Theofanopoulou, MD; Kevin Kunzmann, MSc; Tobias Riexinger, MD; Gerhard Schymik, MD; Matthias Merkel, MD; Claus Schmitt, MD

Background: There is a lack of data on the comparative efficacy and procedural safety of open irrigated radiofrequency (RF) and cryoballoon catheter (CB) ablation for pulmonary vein isolation in patients with paroxysmal atrial fibrillation.

09 octubre 2015

CIRCULATION. Arrhythmia/Electrophysiology. Left Ventricular Ejection Fraction Normalization in Cardiac Resynchronization Therapy and Risk of Ventricular Arrhythmias and Clinical Outcomes. Results From the Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy (MADIT–CRT) Trial

Martin H. Ruwald, MD, PhD; Scott D. Solomon, MD; Elyse Foster, MD; Valentina Kutyifa, MD, PhD; Anne-Christine Ruwald, MD; Saadia Sherazi, MD; Scott McNitt, MS; Christian Jons, MD, PhD; Arthur J. Moss, MD; Wojciech Zareba, MD, PhD

Background: Appropriate guideline criteria for use of implantable cardioverter-defibrillators (ICDs) do not take into account potential recovery of left ventricular ejection fraction (LVEF) in patients treated with CRT-defibrillator.

19 noviembre 2014

CIRCULATION. Long-Term Secondary Prevention After High-Risk Stenting. A Good Drug for a Bad Stent

Jean-Philippe Collet, MD, PhD; Johanne Silvain, MD, PhD; Gilles Montalescot, MD, PhD

Dual antiplatelet therapy (DAPT), the combination of aspirin and an inhibitor of the platelet P2Y12 receptor, is the foundation to prevent acute stent thrombosis (ST), the sudden thrombotic coronary occlusion that can lead to myocardial infarction or death in one third of patients.

16 noviembre 2014

CIRCULATION. Coronary Heart Disease. Global Coronary Flow Reserve Is Associated With Adverse Cardiovascular Events Independently of Luminal Angiographic Severity and Modifies the Effect of Early Revascularization

Viviany R. Taqueti, MD, MPH; Rory Hachamovitch, MD, MS; Venkatesh L. Murthy, MD, PhD; Masanao Naya, MD, PhD; Courtney R. Foster, MS; Jon Hainer, BS; Sharmila Dorbala, MD, MPH; Ron Blankstein, MD; Marcelo F. Di Carli, MD

Background: Coronary flow reserve (CFR), an integrated measure of focal, diffuse, and small-vessel coronary artery disease (CAD), identifies patients at risk for cardiac death. We sought to determine the association between CFR, angiographic CAD, and cardiovascular outcomes.

30 octubre 2014

CIRCULATION. Epidemiology and Prevention. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation

David J. Graham, MD, MPH; Marsha E. Reichman, PhD; Michael Wernecke, BA; Rongmei Zhang, PhD; Mary Ross Southworth, PharmD; Mark Levenson, PhD; Ting-Chang Sheu, MPH; Katrina Mott, MHS; Margie R. Goulding, PhD; Monika Houstoun, PharmD, MPH; Thomas E. MaCurdy, PhD; Chris Worrall, BS; Jeffrey A. Kelman, MD, MMSc

Background: The comparative safety of dabigatran versus warfarin for treatment of nonvalvular atrial fibrillation in general practice settings has not been established.

02 diciembre 2014

CIRCULATION. Interventional Cardiology. Arrhythmia Burden in Elderly Patients With Severe Aortic Stenosis as Determined by Continuous Electrocardiographic Recording. Toward a Better Understanding of Arrhythmic Events After Transcatheter Aortic Valve Replacement

Marina Urena, MD; Salim Hayek, MD; Asim N. Cheema, MD; Vicenç Serra, MD; Ignacio J. Amat-Santos, MD; Luis Nombela-Franco, MD; Henrique B. Ribeiro, MD; Ricardo Allende, MD; Jean-Michel Paradis, MD; Eric Dumont, MD; Vinod H. Thourani, MD; Vasilis Babaliaros, MD; Jaume Francisco Pascual, MD; Carlos Cortés, MD; Bruno García del Blanco, MD; François Philippon, MD; Stamatios Lerakis, MD; Josep Rodés-Cabau, MD

Background: This study sought to evaluate the prevalence of previously undiagnosed arrhythmias in candidates for transcatheter aortic valve replacement (TAVR) and to determine the impact on therapy changes and arrhythmic events after the procedure.

12 diciembre 2014

CIRCULATION. Vascular Medicine. Use and Outcomes Associated With Bridging During Anticoagulation Interruptions in Patients With Atrial Fibrillation. Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)

Benjamin A. Steinberg, MD, MHS; Eric D. Peterson, MD, MPH; Sunghee Kim, PhD; Laine Thomas, PhD; Bernard J. Gersh, MBChB, DPhil; Gregg C. Fonarow, MD; Peter R. Kowey, MD; Kenneth W. Mahaffey, MD; Matthew W. Sherwood, MD, MHS; Paul Chang, MD; Jonathan P. Piccini, MD, MHS; Jack Ansell, MD; on behalf of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients*

Background: Temporary interruption of oral anticoagulation for procedures is often required, and some propose using bridging anticoagulation. However, the use and outcomes of bridging during oral anticoagulation interruptions in clinical practice are unknown.

09 septiembre 2014

CIRCULATION. Valvular Heart Disease. Long-Term Outcomes of Inoperable Patients With Aortic Stenosis Randomly Assigned to Transcatheter Aortic Valve Replacement or Standard Therapy

Samir R. Kapadia, MD; E. Murat Tuzcu, MD; Raj R. Makkar, MD; Lars G. Svensson, MD, PhD; Shikhar Agarwal, MD, MPH; Susheel Kodali, MD; Gregory P. Fontana, MD; John G. Webb, MD; Michael Mack, MD; Vinod H. Thourani, MD; Vasilis C. Babaliaros, MD; Howard C. Herrmann, MD; Wilson Szeto, MD; Augusto D. Pichard, MD; Mathew R. Williams, MD; William N. Anderson, PhD; Jodi J. Akin, MS; D. Craig Miller, MD; Craig R. Smith, MD; Martin B. Leon, MD

Background: The long-term outcomes of transcatheter aortic valve replacement (TAVR) in inoperable patients with severe aortic stenosis remain unknown.

04 septiembre 2014

CIRCULATION. The Challenges of Success. Maintaining Access to High-Quality Percutaneous Coronary Intervention in the Face of Declining Procedural Volumes

Suzanne J. Baron, MD, MSc; Robert W. Yeh, MD, MSc; David J. Cohen, MD, MSc

Over the past several decades, major changes in lifestyle, preventive care, and clinical management have contributed to an impressive reduction in coronary artery disease prevalence, incident acute myocardial infarction, and deaths due to coronary heart disease.